Home › Funds › NEXTBio Capital Management LP › PVLA
NEXTBio Capital Management LP position in PVLA
PALVELLA THERAPEUTICS INC NE · Health Care
NEXTBio Capital Management LP reported holding 80,409 shares of PVLA (PALVELLA THERAPEUTICS INC NE) in its Q3 2026 13F filing — a position valued at US$11.1M, representing 4.83% of its reported portfolio and ranking #9 among its reported holdings. NEXTBio Capital Management LP has disclosed PVLA holdings in 4 of the last 4 reported quarters, going back to Q4 2025.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How NEXTBio Capital Management LP's PVLA position evolved
NEXTBio Capital Management LP first disclosed a stake in PVLA in Q4 2025 at 82,686 shares (US$8.7M). The position peaked in Q2 2026 at 89,909 shares, worth US$13.7M. Across 4 filings, NEXTBio Capital Management LP increased the stake 1 time(s), trimmed it 1 time(s) and left it unchanged 1 time(s). The most recent filing (Q3 2026) shows 80,409 shares valued at US$11.1M — a reduction of -9,500 shares quarter over quarter..
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2025 | 82.69K | $8.65M | New |
| Q1 2026 | 82.69K | $10.31M | Hold |
| Q2 2026 | 89.91K | $13.74M | Add |
| Q3 2026 | 80.41K | $11.09M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About PVLA and 13F data
PVLA (PALVELLA THERAPEUTICS INC NE) is a Health Care company. 83 other funds we track also report a position in PVLA — the largest reported positions include MONTANOVA CAPITAL, LLC (US$173.5M), Frazier Life Sciences Management, L.P. (US$134.8M), First Light Asset Management, LLC (US$118.0M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding PVLA
- MONTANOVA CAPITAL, LLC 1.14M sh · $173.51M · Q2 2026
- Frazier Life Sciences Management, L.P. 882.40K sh · $134.85M · Q2 2026
- First Light Asset Management, LLC 771.90K sh · $117.96M · Q2 2026
- BVF INC/IL 672.79K sh · $102.82M · Q2 2026
- FRONTIER CAPITAL MANAGEMENT CO LLC 478.83K sh · $73.18M · Q2 2026
- EMERALD ADVISERS, LLC 229.40K sh · $31.64M · Q3 2026
- MPM BioImpact LLC 204.03K sh · $31.18M · Q2 2026
- Siren, L.L.C. 207.49K sh · $28.62M · Q3 2026
- First Turn Management, LLC 156.45K sh · $23.91M · Q2 2026
- Bellevue Group AG 155.00K sh · $23.69M · Q2 2026
- Clio Asset Management LLC 86.01K sh · $11.86M · Q3 2026
- Avidity Partners Management LP 70.00K sh · $10.70M · Q2 2026
More on NEXTBio Capital Management LP
FAQ
How long has NEXTBio Capital Management LP held PVLA?
NEXTBio Capital Management LP has disclosed PVLA holdings in 4 of the last 4 reported quarters, going back to Q4 2025.
What is NEXTBio Capital Management LP's current position in PVLA?
As of Q3 2026, NEXTBio Capital Management LP holds 80.41K shares of PVLA (PALVELLA THERAPEUTICS INC NE), valued at $11.09M, representing 4.83% of its reported portfolio and ranking #9.
Has NEXTBio Capital Management LP been buying or selling PVLA?
In the latest 13F filing (Q3 2026), NEXTBio Capital Management LP reduced its position in PVLA. The position peaked in Q2 2026 at 89.91K shares.
Which other funds hold PVLA?
Other major institutional holders of PVLA include MONTANOVA CAPITAL, LLC, Frazier Life Sciences Management, L.P., First Light Asset Management, LLC, among 83 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.